Neurocentrx pharma ltd – Trademark Portfolio

Entity Type: 99

Neurocentrx pharma ltd holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include KETICAP and NEUROCENTRX.

5th Floor, 125 Princes St

Edinburgh, Lothian EH2 4AD

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Neurocentrx pharma ltd's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Neurocentrx pharma ltd have?

Neurocentrx pharma ltd has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Neurocentrx pharma ltd file in?

Neurocentrx pharma ltd files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Neurocentrx pharma ltd's most well-known trademarks?

Neurocentrx pharma ltd's registered trademark portfolio includes well-known marks such as KETICAP and NEUROCENTRX. These are among 2 currently registered trademarks in the portfolio.

What is Neurocentrx pharma ltd's trademark registration success rate?

Neurocentrx pharma ltd has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.